Efficacy and safety of CetuGEX in recurrent/metastatic squamous cell carcinoma of the head and neck (RM-HNSCC): Results from the randomized phase II RESGEX study.
Ulrich Keilholz(German Cancer Research Center), Jérôme Fayette(Université Claude Bernard Lyon 1), Anca Mihailov(Spitalul Clinic Județean de Urgență Cluj-Napoca), Gunnar Folprecht, Sebastián Ochenduszko(Hospital Universitario Doctor Peset), Michael Schenker(Sorbonne Université), Andrzej Kawecki, Sylvie Rottey(Ghent University Hospital), Bożena Kukiełka-Budny, Simona Mihuțiu(University of Oradea), P. Debourdeau(Institut Sainte Catherine), Philippe Schafhausen(University Medical Center Hamburg-Eppendorf), Ilaria Imarisio(University of Pavia), Alfredo Zurlo(European Organisation for Research and Treatment of Cancer), Javier Lavernia(Fundación Instituto Valenciano de Oncología), Alina Turcu, Andreas Dietz(Klinik und Poliklinik für Hals-, Nasen-, Ohrenheilkunde), Cristina Oprean, Bruno Dietrich(Glycotope (Germany)), Bogdan Żurawski
Cited by 5
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k